Bio-Path : FDA Clears Application for Leukemia Trial; Shares Up

By Michael Dabaie

Bio-Path Holdings Inc. said the U.S. Food and Drug Administration cleared the investigational new drug application for BP1002 for a clinical trial in refractory/relapsed acute myeloid leukemia, sending shares higher premarket Tuesday.

The biotechnology company said it anticipates conducting the Phase 1/1b clinical trial at several cancer centers in the U.S., including the Weill Medical College of Cornell University, The University of Texas MD Anderson Cancer Center and the Georgia Cancer Center.

Shares of the company were up 32%, to $7.49, premarket.

Write to Michael Dabaie at [e-mail]

(END) Dow Jones Newswires

08-24-21 0805ET